Group leader+31 20 512 2046 firstname.lastname@example.org
André Bergman studied Medicine and Biology at the VU University in Amsterdam. In 2002 he obtained his PhD from the same university (Prof H Pinedo and Prof G Peters). During his PhD he studied the mechanisms of resistance to the anti-cancer deoxynucleoside gemcitabine. Part of this research was done at Yale University, New Haven, USA. From 1999 on he was trained in Internal Medicine at the University of Utrecht and subsequently as a Medical Oncologist at VU University in Amsterdam. After being registered as a Medical Oncologist, he received a fellowship from the Dutch Cancer Society (KWF). During this fellowship he worked one year in the lab of Prof A Berns at the Netherlands Cancer Institute and one year in the lab of Prof W Nelson, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, USA. Since 2008 he works as a Medical Oncologist at the Antoni van Leeuwenhoek hospital, with a special interest in treating urogenital cancers. After receiving a personal grant from KWF in 2009, a research group was formed exploring the role of the microenvironment in prostate cancer development.